{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:23:06Z","timestamp":1740126186338,"version":"3.37.3"},"reference-count":130,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Significant advances have been made in recent years in the field of Philadelphia\u2010negative acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). New insights into the biology and genetics of <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> as well as novel clinical observations and new drugs are changing the way we diagnose, risk\u2010stratify and treat adult patients with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>. New genetic subtypes and alterations refine risk stratification and uncover new actionable therapeutic targets. The incorporation of more intensive, paediatric and paediatric\u2010inspired approaches for young adults seem to have a positive impact on survival in this population. Minimal residual disease at different time points can assist in tailoring risk\u2010adapted interventions for patients based on individual response. Finally, novel targeted approaches with monoclonal antibodies, immunotherapies and small molecules are moving through clinical development and entering the clinic. The aim of this review is to consolidate the abundance of emerging data and to review and revisit the concepts of risk\u2010stratification, choice of induction and post\u2010remission strategies as well as to discuss and update the approach to specific populations with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, such as young adult, elderly\/unfit and relapsed\/refractory patients with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14916","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T02:42:39Z","timestamp":1509072159000},"page":"705-723","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current challenges and opportunities in treating adult patients with Philadelphia\u2010negative acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-0707","authenticated-orcid":false,"given":"Ofir","family":"Wolach","sequence":"first","affiliation":[{"name":"Institute of Haematology Davidoff Cancer Centre, Beilinson Hospital Rabin Medical Centre Petah\u2010Tikva and Sackler Faculty of Medicine Tel\u2010Aviv University Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Amitai","sequence":"additional","affiliation":[{"name":"Institute of Haematology Davidoff Cancer Centre, Beilinson Hospital Rabin Medical Centre Petah\u2010Tikva and Sackler Faculty of Medicine Tel\u2010Aviv University Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26735"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0153"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.863"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5253"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051761"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-185132"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.123273"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V122.21.839.839","article-title":"Significant improvement of outcome in Adolescents and Young adults (AYAs) aged 15\u201035\u00a0years with Acute Lymphoblastic Leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)","volume":"122","author":"Beck J.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547695"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9924"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22102"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117424"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.139"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.076786"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.14694\/EDBK_156628"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.80.80"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0371-4"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-599894"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.230"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30037"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-551937"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13386"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749507"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V120.21.1493.1493","article-title":"Moderate intensive chemotherapy including CNS\u2010prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph\u2010negative Acute Lymphoblastic Leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL)","volume":"120","author":"Gokbuget N.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.573"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.003"},{"key":"e_1_2_10_37_1","first-page":"14 (V29)","article-title":"First analysis of prognostic factors in elderly Ph\/BCR\u2010ABL negative ALL including comorbidity scores: different factors predict mortality and relapse [abstract]","volume":"31","author":"Gokbuget N.","year":"2008","journal-title":"Onkologie"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.028092"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329441"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144311"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.V126.23.680.680","article-title":"Long\u2010term outcomes after blinatumomab treatment: follow\u2010up of a phase 2 study in Patients (Pts) with Minimal Residual Disease (MRD) positive B\u2010cell precursor Acute Lymphoblastic Leukemia (ALL)","volume":"126","author":"Gokbuget N.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.221.221"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-445098"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412123"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136366"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.123.123"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.170.170"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2010up","volume":"27","author":"Hoelzer D.","year":"2016","journal-title":"Annals of Oncology"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.027862"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-580043"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70114-5"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30376"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-043646"},{"key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V126.23.83.83","article-title":"Frontline Inotuzumab Ozogamicin in combination with low\u2010intensity chemotherapy (mini\u2010hyper\u2010CVD) for older patients with Acute Lymphoblastic Leukemia (ALL)","volume":"126","author":"Jabbour E.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-661702"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726588"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0925"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707414"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-471680"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241943"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.07.013"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4544"},{"key":"e_1_2_10_69_1","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson R.A.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4666"},{"key":"e_1_2_10_71_1","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V78.11.2814.2814","article-title":"Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow\u2010up report","volume":"78","author":"Linker C.A.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2922"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e343"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231217"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264077"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094193"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-580480"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010306"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.1094"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09727"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269571"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2309"},{"key":"e_1_2_10_86_1","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1182\/blood.V104.11.4490.4490","article-title":"Comparison of two regimens for the treatment of elderly patients with Acute Lymphoblastic Leukaemia (ALL)","volume":"104","author":"Offidani M.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_10_87_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.V55.2.199.199","article-title":"Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis","volume":"55","author":"Omura G.A.","year":"1980","journal-title":"Blood"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402006"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.014"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.142"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035091"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037093"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23149"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.7265"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4105"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0073"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08246.x"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24419"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21948"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00778.x"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_2_10_108_1","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/blood.V126.23.3721.3721","article-title":"Salvage chemotherapy with Inotuzumab Ozogamicin (INO) combined with Mini\u2010Hyper\u2010CVD for adult patients with Relapsed\/Refractory (R\/R) Acute Lymphoblastic Leukemia (ALL)","volume":"126","author":"Sasaki K.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401973"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24285"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10965"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558833"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27617"},{"key":"e_1_2_10_116_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): early results of U.S. Intergroup Trial C10403","volume":"124","author":"Stock W.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.506"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095562"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5292"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491092"},{"key":"e_1_2_10_127_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2335"},{"key":"e_1_2_10_128_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V124.21.795.795","article-title":"Nelarabine in Combination with etoposide and cyclophosphamide is active in first relapse of childhood T\u2010Acute Lymphocytic Leukemia (T\u2010ALL) and T\u2010Lymphoblastic Lymphoma (T\u2010LL)","volume":"124","author":"Whitlock J.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_129_1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood.V126.23.794.794","article-title":"Capizzi\u2010Style Methotrexate with Pegasparagase (C\u2010MTX) is superior to High\u2010Dose Methotrexate (HDMTX) in T\u2010Lineage Acute Lymphoblastic Leukemia (T\u2010ALL): results from Children's Oncology Group (COG) AALL0434","volume":"126","author":"Winter S.S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24410"},{"key":"e_1_2_10_131_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T\u2010Lymphoblastic Leukemia (T\u2010ALL) shows excellent outcome, lack of significance of the Early Thymic Precursor (ETP) immunophenotype, and validation of the prognostic value of end\u2010induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood B.L.","year":"2014","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T09:50:07Z","timestamp":1694944207000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/bjh.14916"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14916","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"2017-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}